106. クリオピリン関連周期熱症候群 Cryopyrin-associated periodic syndrome Clinical trials / Disease details


臨床試験数 : 42 薬物数 : 25 - (DrugBank : 4) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 48

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01045772
(ClinicalTrials.gov)
January 20097/1/2010Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany With Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome (CAPS), or Schnitzler Syndrome (SchS)Muckle-Wells Syndrome;Schnitzler SyndromeDrug: rilonaceptCharite University, Berlin, GermanyNULLCompleted18 YearsN/ABoth10Phase 2Germany
2EUCTR2006-004290-97-DE
(EUCTR)
19/12/200817/10/2006A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS). - ACCILTRA1A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS). - ACCILTRA1 The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, sensorineural deafness, general signs of inflammation and secondary amyloidosis. Schnitzler syndrome (SchS) is rare and characterized by chronic, nonpruritic urticaria and a monoclonal immunoglobulin M gammopathy. Symptoms are recurrent fever, bone pain, muscle pain, arthralgia or arthritis.Trade Name: RilonaceptCharité Universitätsmedizin Berlin, Department of Dermatology and AllergyNULLNot RecruitingFemale: yes
Male: yes
Germany
3NCT00288704
(ClinicalTrials.gov)
December 20056/2/2006Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal DesignsFamilial Cold Autoinflammatory Syndrome (FCAS);Familial Cold Urticaria;Muckle-Wells Syndrome (MWS);Genetic Diseases, InbornDrug: rilonacept 160 mg;Drug: PlaceboRegeneron PharmaceuticalsNULLCompleted7 YearsN/AAll104Phase 3United States